Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Odin J. Naderer"'
Publikováno v:
Clinical Pharmacology in Drug Development
GSK1322322 is the first in a new class of antibiotics that inhibit peptide deformylase, necessary for bacterial protein maturation. Previously, low absolute bioavailability was observed for the 1500-mg oral tablet formulation, resulting in a less tha
Autor:
Chester L. Bowen, Liangfu Chen, John Zhu, Keith A. Rodvold, Etienne Dumont, Lori S. Jones, Odin J. Naderer
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:419-423
GSK1322322 is a potent peptide deformylase inhibitor with in vitro and in vivo activity against multidrug-resistant skin and respiratory pathogens. This report provides plasma and intrapulmonary pharmacokinetics, safety, and tolerability of GSK132232
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:2556-2561
GSK1322322 is first in a new class of antibiotics, peptide deformylase inhibitors, and is active against multidrug-resistant respiratory and skin pathogens. Part 1 of this phase 1, randomized, single-dose (1,000 mg) study in 20 healthy volunteers com
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:2005-2009
GSK1322322 is a potent inhibitor of peptide deformylase, an essential bacterial enzyme required for protein maturation. GSK1322322 is active against community-acquired skin and respiratory tract pathogens, including methicillin-resistant Staphylococc
Publikováno v:
Journal of Antimicrobial Chemotherapy. 68:1901-1909
OBJECTIVES GSK1322322 is a potent inhibitor of peptide deformylase, an essential bacterial enzyme required for protein maturation. In this two-part, double-blind, randomized, placebo-controlled, Phase 1 study (study identifier: PDF112668), the safety
Autor:
Lori S. Jones, Elizabeth Thomas, Ganesh M. Sathe, Karen A. Ingraham, James R. Brown, Seda Arat, Stephanie Van Horn, Odin J. Naderer, Christopher M. Traini, David J. Holmes, Aubart Kelly M, Aaron Spivak, George P. Livi
GSK1322322 is a novel antibacterial agent under development, and it has known antibacterial activities against multidrug-resistant respiratory and skin pathogens through its inhibition of the bacterial peptide deformylase. Here, we used next-generati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::502631b051cea56c54e8d41f293ed6ef
https://europepmc.org/articles/PMC4335841/
https://europepmc.org/articles/PMC4335841/
Autor:
Jane Yeo, Joseph J. Eron, Mary Beth Wire, Jean Michel Livrozet, Judith Millard, Eugenio Teofilo, Odin J. Naderer, Christian Trepo, Keikawus Arastéh, Robin Wood
Publikováno v:
Clinical Infectious Diseases. 39:591-594
The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d. regimen and an APV-RTV 1200/200 mg q.d. regimen were studied in a human immunodeficiency virus (HIV)-infected population. The geometric least-
Autor:
Liangfu Chen, Etienne Dumont, Lori S. Jones, Yanli Deng, Odin J. Naderer, Patrick Stump, Chester L. Bowen, Parul Patel, John Zhu, Bo Wen, Clive Felgate, Esaie Pierre, Peter D. Gorycki, Min Lin, Donna Mamaril-Fishman
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 42(8)
GSK1322322 (N-((R)-2-(cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazinyl)-3-oxopropyl)-N-hydroxy-formamide) is an antibiotic in development by GlaxoSmithKline. In this study, we in
Autor:
Bill Spreen, Amy Cutrell, Seth Hetherington, Sue McGuirk, Helen C. Steel, Steve Lafon, Odin J. Naderer, Gwendolyn Powell, Gill Pearce
Publikováno v:
Clinical Therapeutics. 23:1603-1614
Background: Hypersensitivity reactions consist of a variable group of clinical findings and have been described for a wide variety of chemical compounds. Objective: This review characterizes the clinical profile of hypersensitivity to the nucleoside
Publikováno v:
The Journal of Clinical Pharmacology.
GSK1322322 is the first in a new class of antibiotics that targets peptide deformylase (PDF), an essential bacterial enzyme required for protein maturation. This randomized, double-blind, placebo-controlled, eight-cohort phase I trial enrolled 62 hea